Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea

References

• Lee S, Jeong J, Kwak Y, et al. Depression research: where are we now? Mol Brain. 2010;3:8.
   PubMed Web of Science ®Google Scholar
• Langlieb AM, Guico-Pabia CJ Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12. PCC.09r00826. DOI:10.4088/PCC.09r00826blu
   PubMedGoogle Scholar
• Jeon HJ. Epidemiologic studies on depression and suicide. J Korean Med Assoc. 2012;55:322.
   Web of Science ®Google Scholar
• Park JH, Kim KW. A review of the epidemiology of depression in Korea. J Korean Med Assoc. 2011;54:362.
   Web of Science ®Google Scholar
• Chang SM, Hong JP, Cho MJ. Economic burden of depression in South Korea. Soc Psychiatry Psychiatr Epidemiol. 2012;47:683–689.
   PubMed Web of Science ®Google Scholar
• Jeon HJ, Lee J-Y, Lee YM, et al. Lifetime prevalence and correlates of suicidal ideation, plan, and single and multiple attempts in a Korean nationwide study. J Ner Ment Dis. 2010;198:643–646.
   PubMed Web of Science ®Google Scholar
• Jeon HJ, Lee J-Y, Lee YM, et al. Unplanned versus planned suicide attempters, precipitants, methods, and an association with mental disorders in a Korea-based community sample. J Affect Disord. 2010;127:274–280.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2012. Age-standardized suicide rates (per 100 000 population) [Internet]; [cited 2015 Aug 17]. Available from: http://www.who.int/gho/mental_health/suicide_rates/en/.
   Google Scholar
• Wang HR, Bahk WM, Park YM, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Psychiatry Investig. 2014;11:1–11.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349–354.
   PubMed Web of Science ®Google Scholar
• Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry. 2014;14:276.
   PubMed Web of Science ®Google Scholar
• Wang G, Gislum M, Filippov G, et al. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–794.
   Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29:470–482.
   PubMed Web of Science ®Google Scholar
• Soini E, Hallinen T, Brignone M, et al. Cost-utility of vortioxetine in the treatment of major depressive disorder: comparison with agomelatine, bupropion, sertraline and venlafaxine in the finnish setting. Value Health. 2014;17:A459.
   PubMed Web of Science ®Google Scholar
• Kim J, Chalem Y, Di Nicola S, et al. Functional impairment and cognitive dysfunction in depressed patients in South-Korea: Results of perform-K. Value Health. 2014;17:A766–A767.
   PubMed Web of Science ®Google Scholar
• A Guideline to Pharmacoeconomic Evaluation (HIRA). Seoul: Health Insurance Review & Assessment Service (HIRA); 2011.
   Google Scholar
• National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults (Updated Edition). Leicester (UK): The British Psychological Society & The Royal College of Psychiatrists; 2010.
   Google Scholar
• Depression – the review of antidepressants [Internet].Solna: Dental and Pharmaceutical Benefits Agency; 2008. [cited 2015 Aug 17]. Available from: http://www.tlv.se/upload/genomgangen/review-antidepressants.pdf
   Google Scholar
• Mencacci C, Aguglia E, Biggio G, et al. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia. Clinicoecon Outcomes Res. 2013;5:611–621.
   PubMedGoogle Scholar
• Annemans L, Brignone M, Druais S, et al. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium. Pharmacoeconomics. 2014;32:479–493.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Limosin F, Loze JY, Zylberman-Bouhassira M, et al. The course of depressive illness in general practice. Can J Psychiatry. 2004;49:119–123.
   PubMed Web of Science ®Google Scholar
• Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries [Internet]. ClinicalTrials.gov, 2014; [ cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01571453.
   Google Scholar
• A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication (REVIVE) [Internet]. ClinicalTrials.gov, 2014; [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01488071.
   Google Scholar
• Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010;(4):CD006117. DOI:10.1002/14651858.CD006117.pub4
   Web of Science ®Google Scholar
• Bet PM, Hugtenburg JG, Penninx BW, et al. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23:1443–1451.
   PubMed Web of Science ®Google Scholar
• Lee YK, Nam HS, Chuang LH, et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health. 2009;12:1187–1193.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18:911–932.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service (HIRA). HIRA National Health Insurance statistical yearbook. Seoul: Health Insurance Review & Assessment Service; 2012.
   Google Scholar
• Park J-A, Choi S-E. Cost-effectiveness analysis of antidepressants in treatment of major depressive disorder. Korean J Health Econ Policy. 2010;16(2):57–77.
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Afzali HHA, Karnon J, Gray JA. Critical review of model-based economic studies of depression. Pharmacoeconomics. 2012;30:461–482.
   PubMed Web of Science ®Google Scholar
• Zimovetz EA, Wolowacz SE, Classi PM, et al. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012;10:1.
   PubMedGoogle Scholar
• Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826–837.
   PubMed Web of Science ®Google Scholar
• Mullins CD, Onwudiwe NC, De Araújo GTB, et al. Guidance document: global pharmacoeconomic model adaption strategies. Value Health Reg Issues. 2014;5:7–13.
   PubMedGoogle Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model a report of the ISPOR-SMDM modeling good research practices task force–2. Med Decis Making. 2012;32:678–689.
   PubMed Web of Science ®Google Scholar
• Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192:98–105.
   PubMed Web of Science ®Google Scholar